eli lilly and company zepbound

Order byBest matchMost fresh

Wegovy, Zepbound and Eli Lilly

Eli Lilly's Zepbound Outperforms Wegovy In New Obesity Trial, But Trump's Drug Pricing Plan Keeps Retail Traders Wary

Eli Lilly and Co's obesity drug Zepbound led to greater weight loss than Novo Nordisk's Wegovy in a head-to-head Phase 3b trial, according to data published in The New England Journal of Medicine and presented at the European Congress on Obesity.

Stocktwits on MSN · 1d

· 1d · on MSN

Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial

BioSpace · 1d

Lilly’s Zepbound Secures “Superior Benefit-Risk Ratio” Over Novo’s Wegovy

First head-to-head trial found Zepbound beats Wegovy for weight loss

In today’s Health Alert, two popular weight loss drugs went head-to-head in a clinical trial – and one came out on top.

· 23h

· 1d

New study compares Wegovy and Zepbound for the first time

· 1d

Study finds Zepbound may help people lose more weight than Wegovy

Eli Lilly's Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug study

Participants who took Eli Lilly’s tirzepatide, which is sold as Zepbound, lost 50 pounds on average, while those using Novo Nordisk’s semaglutide, also known as Wegovy, lost an average of 33 pounds.

· 1d

Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival’s Wegovy

· 1d

Here’s how much extra weight is lost with Zepbound over Wegovy

18h

Zepbound trims more belly fat than Wegovy, study shows

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the rival medicines.

12d

CVS Health Excludes Zepbound: Why Eli Lilly's 11%+ Drop Looks Overdone

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click for why LLY growth remains strong.

13don MSN

Eli Lilly's Stock Is Up 15% This Year, and Here's Why It Could Take Off Even More

Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly ( LLY 1.09%). It is the most valuable healthcare company in the world, with a market cap of around $800 billion. And yet it may still not be too late to invest in it.